April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Human Myeloid Progenitor Cells Target And Accelerate The Regression Of Hyaloid Vasculature In Normal And Pathological Eyes
Author Affiliations & Notes
  • Valentina Marchetti
    Cell Biology, Scripps Research Institute, La Jolla, California
  • Matthew Wang
    Cell Biology, Scripps Research Institute, La Jolla, California
  • Edith Aguilar
    Cell Biology, Scripps Research Institute, La Jolla, California
  • Mauricio Rosenfeld
    Cell Biology, Scripps Research Institute, La Jolla, California
  • Glen Nemerow
    Cell Biology, Scripps Research Institute, La Jolla, California
  • Martin Friedlander
    Cell Biology, Scripps Research Institute, La Jolla, California
  • Footnotes
    Commercial Relationships  Valentina Marchetti, None; Matthew Wang, None; Edith Aguilar, None; Mauricio Rosenfeld, None; Glen Nemerow, None; Martin Friedlander, None
  • Footnotes
    Support  NIH Grant EY017540
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4855. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Valentina Marchetti, Matthew Wang, Edith Aguilar, Mauricio Rosenfeld, Glen Nemerow, Martin Friedlander; Human Myeloid Progenitor Cells Target And Accelerate The Regression Of Hyaloid Vasculature In Normal And Pathological Eyes. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4855.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : During the initial development of the eye, oxygenation and consequent development of the retina is provided by the choroidal and hyaloidal vasculature. We previously demonstrated that human cord blood (hCB)-derived myeloid cells target retinal vasculature and provide trophic rescue in a model of Oxygen Induced Retinopathy (OIR). We wanted to examine the targeting of these cells to hyaloidal vessels under normal and pathological growth conditions and their role during hyaloidal vessel growth and/or regression.

Methods: : HCB CD14+ cells, infected with Adenovirus 5-GFP, were injected intravitreally in postnatal day seven (P7) mice. Human eGFP+ cells and murine vessels were visualized in vivo using the Heidelberg Spectralis and characterized ex vivo by confocal microscopy at different time points after injection. Branch points and total pixel counts were quantified for each animal. Z-stacks acquired by confocal microscopy were constructed and visualized by Volocity software.

Results: : EGFP+ cells target the hyaloidal vessels exhibiting morphological differentiation around and along the vasculature. Human eGFP+ cells were found incorporating within the vessel lumen. Thin elongated endothelial-like cells were observed within narrow and small vessels; ramified human cells were seen wrapping around large dilated vessels. EGFP+ cells reduced hyaloidal branch points by 60% and the total vessel area by 35% compared to untreated eyes. Targeting, morphology and accelerated hyaloidal vascular regression after treatment with CD14+ cells was similar under conditions of OIR.

Conclusions: : We have identified a human CB-derived CD14+ population that targets hyaloidal vasculature and promotes accelerated regression in normal eyes. Human cells also accelerated hyaloidal vascular regression in the OIR model and, thus, modify the level of oxygen perfusion through the vessels at an early stage in the retinal development. Transcriptomic analysis of injected human cells and target murine tissue reveals differential gene expression associated with the CD14+ cells activities. The use of Adenoviral vectors encoding various trophic factors could modulate the role of CB derived CD14+, providing more efficient and safer methods of ocular gene delivery.

Keywords: oxygen • ischemia • immunohistochemistry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×